Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020). TAKEDA PRESIDENT & CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Takeda's performance in the first half of FY2020 demonstrates the resilience of our business model, the depth of our portfolio and the commitment of our employees, who continue to serve patients and communities glob

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan's Ministry of Health Labour and Welfare (MHLW). Moderna has previously announced that the 30,000 participant Phase 3 clinical tria

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan.

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America (THSNA), highlighting Takeda's commitment to advancing personalized care in people living with bleeding disorders. These studies may help provide further data to healthcare providers regarding treatment personalization in patients with hemophilia and von Willebrand's disease (VWD). “When l

Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020

Accenture Plc

OSAKA, Japan & NEW YORK & SEATTLE--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and Amazon Web Services, Inc. (AWS) have entered into a five-year strategic agreement to accelerate Takeda’s digital transformation. Not only will patients benefit from Takeda’s ability to respond with greater speed, agility, and insights across the value chain, but customers, employees, and partners will also benefit. This long-term collaboration wil

Takeda Accelerates Digital Transformation with Accenture and AWS

A group led by Takeda Pharmaceutical Company Limited (NYSE: TAK) has begun manufacturing a blood plasma treatment for COVID-19, even as late-stage human testing remains pending, the company’s CEO Christophe Weber told Reuters Monday. What Happened: The CoVIg Plasma Alliance, composed of CSL Behring, Biotest AG as well as other firms, began Phase 3 testing last Friday after the trials were delayed for months, according to Reuters.

Takeda-Led Group Begins Manufacturing COVID-19 Plasma Treatment, Says Confident Of Efficacy

Arrowhead Pharmaceuticals

Arrowhead's New Deal With Takeda Strengthens The Company's Value Proposition

Takeda Broadens Its Rare Disease Portfolio By Partnering With Arrowhead

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Takeda and Arrowhead announced a collaboration and licensing agreement to develop ARO-AAT, a Ph. 2 investigational RNAi therapy to treat AATLD.

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Takeda has underperformed ever since it first expressed interest in buying Shire, and good progress on asset sales and cost synergies has gone largely unrewarded.

Takeda Executing On Synergies And Asset Sales, But Not Getting Much Credit

AbbVie

CVS Health

Altria

ONEOK

AT&T

Chasing high yields alone will ruin an income investor’s returns, so we look at these picks that offer a balance of stability and dividend income growth. The post 7 Dividend Stocks Perfect for a Retiree’s Portfolio appeared first on InvestorPlace.

7 Dividend Stocks Perfect for a Retiree’s Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc.

Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference.

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza Health”).

Takeda to Divest TachoSil® to Corza Health for €350 Million

AstraZeneca

Biogen

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Perrigo

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

OSAKA, Japan--(BUSINESS WIRE)--Takeda opened a new R&D cell therapy manufacturing facility, which will accelerate Takeda's efforts to develop next-generation cell therapies.

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

OSAKA, JAPAN--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has approved a label update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) broadening its use and making it the first and only facilitated subcutaneous immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (SID). With the update, HYQVI

European Medicines Agency Approves Label Update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase), Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies

Gilead Sciences

Regeneron Pharmaceuticals

vTv Therapeutics

Zoetis

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

5 of the Best Pharmaceutical Stocks to Buy Right Now

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.

Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma

SEATTLE, Sept. 9, 2020 /PRNewswire/ -- Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced a new research collaboration with Takeda Pharmaceutical.

Presage Announces New, Multi-Project Collaboration with Takeda for Phase 0 Studies of Novel Cancer Agents with CIVO® Technology

LEEDS, England, Sept. 8, 2020 /PRNewswire/ -- Effiris delivers state-of-the-art secondary pharmacology models, where each model has had the opportunity to learn from the private data of all pharmaceutical collaborators.

Takeda Joins Lhasa's Effiris Consortium - Powering Model Development Through Privacy-Preserving Data Transfer

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products.

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

Blackstone Group

As part of what may seem like a confusing move to some, asset manager Blackstone Group Inc (NYSE: BX) agreed to acquire the consumer health care business of Japan-based Takeda Pharmaceutical for 242 billion yen (£1.75 billion, $2.29 billion), The Wall Street Journal reported. Who is Takeda?

Why Blackstone Spent $2.3B on a drugmaker

Blackstone (BX) will be acquiring Takeda Consumer Healthcare, which is the consumer division of Takeda Pharmaceutical (TAK).

Blackstone to Buy Takeda Pharmaceutical Consumer Unit

Takeda Pharmaceuticals (NYSE: TAK) shares are trading higher on Monday after Blackstone signed a definitive agreement to acquire Takeda Consumer Healthcare Company.

Why Takeda Pharmaceuticals Is Trading Higher Today

News for Takeda Pharmaceutical Stock (TAK)